Phase 3 trial of trofinetide will take place in the US during the latter half of 2019
4 February 2019 – Neuren Pharmaceuticals advised the Australian Stock Exchange, Melbourne, of a statement released by ACADIA Pharmaceuticals about its plans for the Phase 3 trial of trofinetide in Rett syndrome. As with Phases 1 and 2, the trial will be held in the US. In part, ACADIA stated that “We…